-
EP4289852
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4289852
| EP4289852 - 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 10.11.2023 Database last updated on 19.10.2024 | |
| Former | The international publication has been made Status updated on 12.08.2022 | Most recent event Tooltip | 06.09.2024 | Change - representative | Applicant(s) | For all designated states NovaOnco JS Therapeutics Co., Ltd. Rm. P03-1041 No. 101, Xinxu Avenue Xuzhou Economic and Technological Development Zone Jiangsu Province 221132 / CN | [2024/40] |
| Former [2023/50] | For all designated states Medshine Discovery Inc. Room 218, No. 9 Gaoxin Road Jiangbei New District Nanjing, Jiangsu 210032 / CN | Inventor(s) | 01 /
XU, Yangyang Shanghai 200131 / CN | 02 /
WU, Wentao Shanghai 200131 / CN | 03 /
TAN, Haizhong Shanghai 200131 / CN | 04 /
ZAHNG, Dongkai Shanghai 200131 / CN | 05 /
SUN, Jikui Shanghai 200131 / CN | 06 /
ZHANG, Yang Shanghai 200131 / CN | 07 /
CHEN, Shuhui Shanghai 200131 / CN | [2023/50] | Representative(s) | Høiberg P/S Adelgade 12 1304 Copenhagen K / DK | [N/P] |
| Former [2023/50] | Dehns St. Bride's House 10 Salisbury Square London EC4Y 8JD / GB | Application number, filing date | 22749004.2 | 26.01.2022 | [2023/50] | WO2022CN74110 | Priority number, date | CN202110172946 | 08.02.2021 Original published format: CN202110172946 | CN202110655630 | 11.06.2021 Original published format: CN202110655630 | CN202110864387 | 29.07.2021 Original published format: CN202110864387 | CN202111137961 | 27.09.2021 Original published format: CN202111137961 | CN202111473661 | 29.11.2021 Original published format: CN202111473661 | [2023/50] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022166725 | Date: | 11.08.2022 | Language: | ZH | [2022/32] | Type: | A1 Application with search report | No.: | EP4289852 | Date: | 13.12.2023 | Language: | EN | [2023/50] | Search report(s) | International search report - published on: | CN | 11.08.2022 | Classification | IPC: | C07D495/04, A61K31/519, A61P35/00 | [2023/50] | CPC: |
C07D495/04 (EP,US);
A61P35/00 (US);
C07D519/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/50] | Title | German: | 5,6-DIHYDROTHIENO[3,4-H CHINAZOLIN-VERBINDUNG | [2023/50] | English: | 5,6-DIHYDROTHIENO[3,4-H]QUINAZOLINE COMPOUND | [2023/50] | French: | COMPOSÉ DE 5,6-DIHYDROTHIÉNO[3,4-H]QUINAZOLINE | [2023/50] | Entry into regional phase | 06.09.2023 | Translation filed | 06.09.2023 | National basic fee paid | 06.09.2023 | Search fee paid | 06.09.2023 | Designation fee(s) paid | 06.09.2023 | Examination fee paid | Examination procedure | 06.09.2023 | Amendment by applicant (claims and/or description) | 06.09.2023 | Examination requested [2023/50] | Fees paid | Renewal fee | 26.12.2023 | Renewal fee patent year 03 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]CN1826343 (PHARMACIA ITALIA SPA [IT]); | [A]CN101484457 (VERTEX PHARMA [US]); | [A]WO2009112524 (4SC AG [DE], et al); | [A]CN101563351 (NERVIANO MEDICAL SCIENCES SRL [IT]); | [A]CN101824043 (VERTEX PHARMA); | [A]CN101952291 (VERTEX PHARMA); | [A]WO2012013557 (NERVIANO MEDICAL SCIENCES SRL [IT], et al); | [A]CN103097388 (BOEHRINGER INGELHEIM INT); | [A]CN103122001 (TAKEDA PHARMACEUTICAL); | [A]WO2014145909 (DANA FARBER CANCER INST INC [US]); | [A]WO2020063788 (BETTA PHARMACEUTICALS CO LTD [CN]) |